Skip to main
ABVX

Abivax SA (ABVX) Stock Forecast & Price Target

Abivax SA (ABVX) Analyst Ratings

Based on 11 analyst ratings
Buy
Strong Buy 27%
Buy 73%
Hold 0%
Sell 0%
Strong Sell 0%

Bulls say

Abivax SA is currently conducting Phase 3 clinical trials for obefazimod, which has demonstrated statistically significant improvements in clinical remission for patients with ulcerative colitis, particularly in those with inadequate responses to advanced treatments. The growing market for ulcerative colitis therapies, projected to increase from $9.2 billion in 2025 to $21.2 billion by 2032, presents a substantial opportunity for the company, further underscored by the successful meeting of EMA co-primary endpoints in its studies. Additionally, the rapid therapeutic effect of obefazimod and the expertise of Abivax's management team contribute to a strong outlook for the company in an established market with significant unmet needs.

Bears say

Abivax SA's stock faces a negative outlook primarily due to the disappointing translation of initial induction results into meaningful maintenance efficacy, raising concerns reminiscent of previous failures from competitors in the sector. The company's low ~3% placebo response rate in its induction trial further undermines confidence in the robustness and real-world applicability of its data. Additionally, the low efficacy bar set by previous oral therapies, which have struggled with efficacy and safety, does not provide a strong foundation for obefazimod's commercial success in a competitive and challenging therapeutic landscape.

Abivax SA (ABVX) has been analyzed by 11 analysts, with a consensus rating of Buy. 27% of analysts recommend a Strong Buy, 73% recommend Buy, 0% suggest Holding, 0% advise Selling, and 0% predict a Strong Sell.

This aggregate rating is based on analysts' research of Abivax SA and is not a guaranteed prediction by Public.com or investment advice.

Order type

Buy in

Order amount

Est. shares

0 shares

Sign up to buy

FAQs About Abivax SA (ABVX) Forecast

Analysts have given Abivax SA (ABVX) a Buy based on their latest research and market trends.

According to 11 analysts, Abivax SA (ABVX) has a Buy consensus rating as of Feb 19, 2026. This rating is provided by third-party analysts and is not investment advice from Public.com.

Wall Street analysts have set a price target of $126.73, reflecting a 0.00% increase from the current stock price.

Financial analysts have set a price target of $126.73, indicating a 0.00% increase from the current stock price, but ratings and forecasts are frequently updated based on market conditions, earnings reports, and industry trends. This prediction is provided by third-party analysts and is not investment advice from Public.com.

Abivax SA (ABVX)


Order type

Buy in

Order amount

Est. shares

0 shares

Sign up to buy
Disclaimer: Any investment listed here, which may be available on the Public platform, is intended to be used for informational purposes only, should not be the sole basis for making an investment decision, and is not a recommendation or advice.